MetaCap

CorMedix Inc. (CRMD)

NASDAQ: CRMDHealth CareBiotechnology: Pharmaceutical PreparationsUSD

5.27+0.19 (+3.74%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

CRMD stock chart

Technical analysis

Key statistics

All statistics
Market cap
$419.16M
52-week range
4.47 – 13.02
Day range
4.95 – 5.32
Volume / Avg
3.61M / 1.44M
Beta
—

52-week range

$4.47$13.02

CRMD stock today

CorMedix (CRMD) closed at $5.27 on Nov 20, up 3.74% (+$0.19), versus the S&P 500's 3.70% decline. Volume was 2.5x the average at 3.61M shares, a sign of unusually heavy trading. At this level, CRMD sits near the bottom of its 52-week range of $4.47 to $13.02: 59.5% below the high, set on Dec 30, 2025 and 17.9% above the low.

CRMD is down 54.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 45.6%. CorMedix trades at 8.2x its trailing twelve-month earnings per share of $0.64. Its forward P/E of 15.1x is higher than the trailing multiple, which means analysts expect earnings to decline over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About CorMedix

Company profile

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Joseph Todisco MBA
Headquarters
Parsippany, NJ
Employees
191

Financial highlights

Full financials

In fiscal 2025, CorMedix generated $311.7 million in revenue, up 617.0% from fiscal 2024. Net income was $163.1 million, for a net margin of 52.3% versus a median of -11991.2% in the prior 5 years. Gross margin was 88.5% (down from 92.7%) and operating margin 48.2%.

CorMedix annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$311.71M$43.47M—$65.41K$190.94K
Growth+617.03%——-65.74%-20.19%
Net income$163.06M$-17.93M$-46.34M$-29.70M$-28.21M
EPS (diluted)$2.04$-0.30$-0.91$-0.74$-0.75

Analyst forecast

Forecast

Consensus (5 analysts)

buy

Avg. price target

$13.80+161.86%

  • Strong buy 3
  • Buy 2
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $12.00High $17.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-0.04 vs $-0.09
Surprise
+55.56%

CRMD news

All CRMD news

CorMedix peers

Health Care sector
CRMD peer companies
CompanyPrice% ChgMarket capCompare
PRTAProthena Corporation plc8.22-2.14%$422.10Mvs CRMD
ARVNArvinas Inc.6.46-4.15%$423.03Mvs CRMD
OVIDOvid Therapeutics Inc.2.20-5.98%$415.21Mvs CRMD
EOLSEvolus Inc.6.52-6.86%$431.55Mvs CRMD
INDPIndaptus Therapeutics Inc.2.82-9.90%$433.16Mvs CRMD
AQSTAquestive Therapeutics Inc.3.46-6.61%$434.88Mvs CRMD
CAPRCapricor Therapeutics Inc.7.59+0.80%$441.30Mvs CRMD
LYELLyell Immunopharma Inc.13.80+1.62%$441.82Mvs CRMD

Indexes, lists and sector

CorMedix stock FAQ

What is CorMedix's stock price today?

CRMD last traded at $5.27 as of Nov 20, 4:00 PM EST, up 3.74% on the day. Prices are delayed at least 15 minutes.

Does CorMedix pay a dividend?

No. CorMedix does not currently pay a regular cash dividend.

What is CRMD's P/E ratio?

CRMD trades at a trailing P/E ratio of 8.23 and a forward P/E of 15.06.

Who is CorMedix's CEO?

Mr. Joseph Todisco MBA is the chief executive officer of CorMedix Inc., which has about 191 employees.

Has CRMD ever split its stock?

Yes. The most recent CRMD stock split was a 1-for-5 split on Mar 26, 2019.

What is the CRMD 52-week high?

The 52-week high for CRMD is $13.02 and the 52-week low is $4.47. The stock is currently 59.5% below its high.

Compare CRMD